Abstract

The antibiotic daptomycin is produced by the Gram-positive bacterium Streptomyces roseosporus and is the first in a new class of investigational drugs called lipopeptides that is being developed by Cubist for the treatment of serious and life-threatening infections caused by Gram-positive pathogens. The goal of this phase I application is to develop a system that will allow the rapid manipulation of the daptomycin biosynthetic gene cluster. These tools would then be used in phase II of the application to elucidate the structure activity realtionships (SAR) of daptomycin and use this information to create derivatives of daptomycin with increased potency against vancomycin resistant pathogens. ? ?

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44GM068173-02
Application #
6788578
Study Section
Special Emphasis Panel (ZRG1-SSS-L (10))
Program Officer
Jones, Warren
Project Start
2003-07-01
Project End
2006-08-31
Budget Start
2004-09-30
Budget End
2005-08-31
Support Year
2
Fiscal Year
2004
Total Cost
$500,000
Indirect Cost

  Institution

Name
Cubist Pharmaceuticals, Inc.
Department
Type
DUNS #
City
Lexington
State
MA
Country
United States
Zip Code
02421

  Publications

Nguyen, Kien T; He, Xiaowei; Alexander, Dylan C et al. (2010) Genetically engineered lipopeptide antibiotics related to A54145 and daptomycin with improved properties. Antimicrob Agents Chemother 54:1404-13
Nguyen, Kien T; Ritz, Daniel; Gu, Jian-Qiao et al. (2006) Combinatorial biosynthesis of novel antibiotics related to daptomycin. Proc Natl Acad Sci U S A 103:17462-7